Article

Longitudinal plasma proteomics separates diagnostic differences from progression-linked changes in Alzheimer’s disease

2026-07-10

Abstract excerpt

Most plasma proteomic studies in Alzheimer’s disease (AD) compare cases and controls cross-sectionally, leaving unresolved which AD-associated proteins mark diagnostic states and which are linked to disease progression. Using longitudinal SomaScan profiling from the Global Neurodegeneration Proteomics Consortium (13,449 participants, 17,269 samples, 7,362 aptamers), we separated baseline AD differences from AD-spe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 36ac3ece-751d-5988-9164-346e77a2ee0a
DOI: 10.64898/2026.07.01.26356385

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Longitudinal plasma proteomics separates diagnostic differences from progression-linked changes in Alzheimer’s diseaseDOI 10.64898/2026.07.01.26356385Read

Mapping the circulating proteome across neurodegeneration: A harmonized, consortium-scale framework for uncovering molecular pathophysiologySemantic proximity Read

Proteomic Signatures of Neuropathological Alterations in Alzheimer’s Disease: Insights from the Bio-Hermes StudySemantic proximity Read

Systematic proteomics in Autosomal dominant Alzheimer’s disease reveals decades-early changes of CSF proteins in neuronal death, and immune pathwaysSemantic proximity Read

Identification of Novel Biomarkers for Alzheimer’s Disease and Related Dementias Using Unbiased Plasma ProteomicsSemantic proximity Read

Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures across the Alzheimer disease continuumSemantic proximity Read

A genetic and proteomic comparison of key AD biomarkers across tissuesSemantic proximity Read

Proteomic Signatures of Neuropathological Alterations in Alzheimer’s Disease: Insights from the Bio-Hermes StudySemantic proximity Read

Multi-tissue proteomic signatures of Alzheimer’s disease: a systematic investigation in brain, CSF, blood and an exploratory study in tearsSemantic proximity Read

Novel Plasma Proteins Associated With Alzheimer’s Disease Risk in APOE ε4 Carriers and Non-carriersSemantic proximity Read

Proteomic landscape of Alzheimer’s disease: emerging technologies, advances and insights (2021 – 2025)Semantic proximity Read

Plasma vs. serum: which is better for proteomic blood biomarker analysis? Evaluation of the novel NULISA platformSemantic proximity Read

Redefining ALS: Large-scale proteomic profiling reveals a prolonged pre-diagnostic phase with immune, muscular, metabolic, and brain involvementSemantic proximity Read